Description: Amino Acids & Building Blocks|Amino Acids and Derivatives#Others|nNOS#Others

Description: Amino Acids & Building Blocks|Amino Acids and Derivatives#Others|nNOS#Others

Description: NO synthase inhibitor

Description: Amino Acids & Building Blocks|Amino Acids and Derivatives#Others|nNOS#Others

Description: NO synthase inhibitor

Description: Amino Acids & Building Blocks|Amino Acids and Derivatives#Others|nNOS#Others

Description: L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: 8MTTis the first commercially available, full-length, genetically detoxified tetanus toxin. As a full-length protein, 8MTT contains all the tetanus toxin epitopes. 8MTT is more thermal and pH stable than CRM197. 8MTT is comparable to tetanus toxoid as a carrier protein. At 150 kDa, 8MTT is about 3 times the mass of CRM197and has ~35 surface accessible lysines vs ~10 for the latter, allowing for higher hapten loading.

Description: Amino-Dextran (AmDex, AECM-dextran) consists of dextran functionalized with primary amines. (See “Diagram” Tab for the structure of FinaBio amino dextran.) Our AmDex is prepared from dextran using a protocol yielding a stable, amino functionalized dextran that is superior to the more commonly used reductive amination methods. The molecular weight profile of Fina Biosolutions’ AmDex is essentially unchanged from the starting dextran, as determined by analytical size exclusion chromatography. The product is desalted and lyophilized. We do extensive processing and testing to ensure that free amino reagent is removed, resulting in a consistent product with minimal lot-to-lot variation. We have found that many commercial lots of amino-dextran contain variable amounts of dextran and that the amine content is often incorrect. Furthermore, the actual polymer molecular weight distributions of these preparations can vary extensively from the indicated molecular weight. These issues can mean that optimization data is based on incorrect information. Lot-to-lot variations means that protocols may need to be revised when a new lot of AmDex is used. Please contact us if you need a ratio that is not listed.

Description: Amino-Dextran (AmDex, AECM-dextran) consists of dextran functionalized with primary amines. (See “Diagram” Tab for the structure of FinaBio amino dextran.) Our AmDex is prepared from dextran using a protocol yielding a stable, amino functionalized dextran that is superior to the more commonly used reductive amination methods. The molecular weight profile of Fina Biosolutions’ AmDex is essentially unchanged from the starting dextran, as determined by analytical size exclusion chromatography. The product is desalted and lyophilized. We do extensive processing and testing to ensure that free amino reagent is removed, resulting in a consistent product with minimal lot-to-lot variation. We have found that many commercial lots of amino-dextran contain variable amounts of dextran and that the amine content is often incorrect. Furthermore, the actual polymer molecular weight distributions of these preparations can vary extensively from the indicated molecular weight. These issues can mean that optimization data is based on incorrect information. Lot-to-lot variations means that protocols may need to be revised when a new lot of AmDex is used. Please contact us if you need a ratio that is not listed.

Description: Amino-Dextran (AmDex, AECM-dextran) consists of dextran functionalized with primary amines. (See “Diagram” Tab for the structure of FinaBio amino dextran.) Our AmDex is prepared from dextran using a protocol yielding a stable, amino functionalized dextran that is superior to the more commonly used reductive amination methods. The molecular weight profile of Fina Biosolutions’ AmDex is essentially unchanged from the starting dextran, as determined by analytical size exclusion chromatography. The product is desalted and lyophilized. We do extensive processing and testing to ensure that free amino reagent is removed, resulting in a consistent product with minimal lot-to-lot variation. We have found that many commercial lots of amino-dextran contain variable amounts of dextran and that the amine content is often incorrect. Furthermore, the actual polymer molecular weight distributions of these preparations can vary extensively from the indicated molecular weight. These issues can mean that optimization data is based on incorrect information. Lot-to-lot variations means that protocols may need to be revised when a new lot of AmDex is used. Please contact us if you need a ratio that is not listed.

Description: Amino-Dextran (AmDex, AECM-dextran) consists of dextran functionalized with primary amines. (See “Diagram” Tab for the structure of FinaBio amino dextran.) Our AmDex is prepared from dextran using a protocol yielding a stable, amino functionalized dextran that is superior to the more commonly used reductive amination methods. The molecular weight profile of Fina Biosolutions’ AmDex is essentially unchanged from the starting dextran, as determined by analytical size exclusion chromatography. The product is desalted and lyophilized. We do extensive processing and testing to ensure that free amino reagent is removed, resulting in a consistent product with minimal lot-to-lot variation. We have found that many commercial lots of amino-dextran contain variable amounts of dextran and that the amine content is often incorrect. Furthermore, the actual polymer molecular weight distributions of these preparations can vary extensively from the indicated molecular weight. These issues can mean that optimization data is based on incorrect information. Lot-to-lot variations means that protocols may need to be revised when a new lot of AmDex is used. Please contact us if you need a ratio that is not listed.

Description: Amino-Dextran (AmDex, AECM-dextran) consists of dextran functionalized with primary amines. (See “Diagram” Tab for the structure of FinaBio amino dextran.) Our AmDex is prepared from dextran using a protocol yielding a stable, amino functionalized dextran that is superior to the more commonly used reductive amination methods. The molecular weight profile of Fina Biosolutions’ AmDex is essentially unchanged from the starting dextran, as determined by analytical size exclusion chromatography. The product is desalted and lyophilized. We do extensive processing and testing to ensure that free amino reagent is removed, resulting in a consistent product with minimal lot-to-lot variation. We have found that many commercial lots of amino-dextran contain variable amounts of dextran and that the amine content is often incorrect. Furthermore, the actual polymer molecular weight distributions of these preparations can vary extensively from the indicated molecular weight. These issues can mean that optimization data is based on incorrect information. Lot-to-lot variations means that protocols may need to be revised when a new lot of AmDex is used. Please contact us if you need a ratio that is not listed.